Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accounts Payables: 2022-2024

Historic Accounts Payables for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $2.5 million.

  • Stoke Therapeutics' Accounts Payables rose 136.26% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 136.26%. This contributed to the annual value of $2.5 million for FY2024, which is 47.37% up from last year.
  • Per Stoke Therapeutics' latest filing, its Accounts Payables stood at $2.5 million for FY2024, which was up 47.37% from $1.7 million recorded in FY2023.
  • Over the past 5 years, Stoke Therapeutics' Accounts Payables peaked at $2.5 million during FY2024, and registered a low of $766,000 during FY2022.
  • For the 3-year period, Stoke Therapeutics' Accounts Payables averaged around $1.7 million, with its median value being $1.7 million (2023).
  • Data for Stoke Therapeutics' Accounts Payables shows a peak YoY soared of 121.28% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Stoke Therapeutics' Accounts Payables stood at $766,000 in 2022, then spiked by 121.28% to $1.7 million in 2023, then surged by 47.37% to $2.5 million in 2024.